| A Study of SH3765 Tablets in Combination With Fulvestrant in Patients With HR+/HER2- Advanced Breast Cancer. (NCT07557004) | Nanjing Sanhome Pharmaceutical, Co., Ltd. | 2025-09-30 |
| A Study of SH006 Injection Combination Therapy in Patients With Advanced Solid Tumors (NCT07362264) | Nanjing Sanhome Pharmaceutical, Co., Ltd. | 2025-07-01 |
| A Study of SH009 Injection in Patients With Advanced Solid Tumors. (NCT07390838) | Nanjing Sanhome Pharmaceutical, Co., Ltd. | 2025-05-16 |
| SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations (NCT06080776) | Nanjing Sanhome Pharmaceutical, Co., Ltd. | 2023-05-11 |
| A Study to Investigate Safety and Tolerability of SH3765 Tablet in Patients With Advanced Malignant Tumor (NCT05015309) | Nanjing Sanhome Pharmaceutical, Co., Ltd. | 2021-09-01 |
| The Effect of Itraconazole and Rifampicin on the Pharmacokinetics of SH-1028 (NCT04808648) | Nanjing Sanhome Pharmaceutical, Co., Ltd. | 2021-04-06 |
| A Study to Investigate Safety and Tolerability of SH3809 Tablet in Patients With Advanced Solid Tumors (NCT04843033) | Nanjing Sanhome Pharmaceutical, Co., Ltd. | 2021-04-02 |
| A Phase 1 Study of SH1573 Capsules in Subjects With Refractory or Relapsed Acute Myelogenous Leukemia (NCT04806659) | Nanjing Sanhome Pharmaceutical, Co., Ltd. | 2020-08-04 |
| A Study of SHC014748M in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (NCT04470141) | Nanjing Sanhome Pharmaceutical, Co., Ltd. | 2020-08-01 |
| A Study to Investigate Safety and Tolerability of SH3051 Capsule in Patients With Advanced Solid Tumors (NCT04423380) | Nanjing Sanhome Pharmaceutical, Co., Ltd. | 2020-05-14 |
| The Absorption, Metabolism and Excretion of [14C]SH-1028 in Chinese Healthy Male Volunteers (NCT04810533) | Nanjing Sanhome Pharmaceutical, Co., Ltd. | 2020-05-13 |
| Efficacy and Safety of SHC014748M in Patients With Relapsed or Refractory Follicular (FL) or Marginal Zone (MZL) Lymphoma (NCT04431089) | Nanjing Sanhome Pharmaceutical, Co., Ltd. | 2020-05-09 |
| A Study of SH-1028 Tablets Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NCT04239833) | Nanjing Sanhome Pharmaceutical, Co., Ltd. | 2020-01-31 |
| A Food-Effect Study of SHC014748M in Healthy Subjects (NCT04006860) | Nanjing Sanhome Pharmaceutical, Co., Ltd. | 2019-07-01 |
| Pharmacokinetic Study of SH-1028 Tablets in Healthy Subjects Under Fasting and Fed Conditions (NCT03973632) | Nanjing Sanhome Pharmaceutical, Co., Ltd. | 2019-07-01 |
| SH229 Tablets Combined With Daclatasvir Dihydrochloride Tablets in Treatment Adult Patients With Chronic Hepatitis C (NCT04070235) | Nanjing Sanhome Pharmaceutical, Co., Ltd. | 2019-03-29 |
| A Study to Evaluate the Safety and Efficacy of SH-1028 in Locally Advanced or Metastatic NSCLC (NCT03823807) | Nanjing Sanhome Pharmaceutical, Co., Ltd. | 2019-03-01 |
| A Drug-drug Interaction Study of SH229 Tablets and Daclatasvir Dihydrochloride Tablets in Healthy Subjects (NCT03748745) | Nanjing Sanhome Pharmaceutical, Co., Ltd. | 2018-11-19 |
| Safety and Tolerability of SH-1028 in Patients With Advanced Solid Cancer (NCT03618043) | Nanjing Sanhome Pharmaceutical, Co., Ltd. | 2018-09-13 |
| Safety, Tolerability, and Pharmacokinetics of SHC014748M in Patients With Indolent B-Cell Hematologic Malignancies (NCT03588598) | Nanjing Sanhome Pharmaceutical, Co., Ltd. | 2018-09-07 |
| Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of SH229 in Patients With HCV Infection (NCT03588923) | Nanjing Sanhome Pharmaceutical, Co., Ltd. | 2018-07-07 |
| Safety, Tolerability and Pharmacokinetics of SH-1028 in Patients With Advanced NSCLC (NCT03603262) | Nanjing Sanhome Pharmaceutical, Co., Ltd. | 2018-04-25 |